Healthy
Conditions
Brief summary
This study will compare the pharmacokinetics and pharmacodynamics, after single subcutaneous application, in healthy men, between filgrastim formulation, produced by Megalabs (test product) and Granulokine® (reference product) Amgen.
Interventions
BIOLOGICALFilgrastim Megalabs
Filgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose
BIOLOGICALGranulokine
Granulokine 5 μg/Kg/day, subcutaneous single dose
Sponsors
Megalabs
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy eligible participants able to read, understand and sign the latest version of the Informed Consent Form (ICF) approved by the Research Ethics Committee (CEP) * Males aged between 18 and 55 years * Be characterized as a healthy research participant, based on medical history general physical examination and vital signs, laboratory tests and electrocardiogram (ECG), * Not indicating any evidence of disease * Body weight between 60-100 kg * Body Mass Index (BMI) ≥ 18.5 and ≤ 29.9 Kg / m2 * Negative test for coronavirus
Exclusion criteria
* Present one or more flu-like symptoms such as: fever (body temperature greater than or equal to 37.8 ° C), cough, dyspnoea, myalgia and fatigue, respiratory symptoms, gastrointestinal symptoms (such as diarrhea) within 7 days prior to the hospitalization period (all periods) * Direct and significant medical contact with people who tested positive for coronavirus testing within 14 days prior to the hospitalization period (all periods) * Living in the same household as people who are in the risk group with the worst prognosis for coronavirus infection, such as individuals over 60, individuals with respiratory problems, immunosuppressed or those with chronic diseases, such as heart or diabetes (all periods) * Participants diagnosed with malignant disease in the last 5 years, with the exception of successfully treated basal cell carcinoma * Participants with a previous diagnosis of severe asthma, sickle cell anemia, idiopathic urticaria or anaphylaxis * Participants with chronic diseases and, therefore, who regularly use medications * Being a smoker or quitting less than 6 months ago * Participants who consume more than 5 cups of tea or coffee a day and who cannot - abstain during the trial period * History of alcohol and illicit drug abuse * Electrocardiogram (ECG) findings that, at the investigator's discretion, may compromise participation in the trial * History or presence of gastrointestinal or liver diseases or any other condition that interferes with the absorption, distribution, excretion or metabolism of the drug * Use of lithium 2 weeks before and / or after medication administration * Participants who are hypersensitive or contraindicated to use any of the components of the formulation * Research participants who have participated in clinical trial protocols in the last 12 (twelve) months (Resolution CNS 251, of August 7, 1997, item III, subitem J) * Have donated blood (\> 500 mL) or have undergone major surgery in the 3 (three) months preceding the date of signing the informed consent form * Have received any vaccine in the 3 (three) months preceding the date of signing the informed consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of AUC 0-t in healthy volunteers for test and reference. | 17 days |
| Evaluation of Cmax in healthy volunteers for test and reference. | 17 days |
| Evaluation of absolute neutrophil count (ANC) in healthy volunteers for test and reference. | 17 days |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of CD34+ count for test and reference | 17 days |
Contacts
Primary ContactMarcos Giusti, MD
Backup ContactVictoria Rodríguez, MD
Outcome results
None listed